Atalanta Sosnoff Capital’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-402,714
Closed -$25.3M 114
2026
Q1
$25.3M Sell
402,714
-249,281
-38% -$19.9M 0.54% 45
2025
Q4
$62.2M Sell
651,995
-43,573
-6% -$4.27M 1.21% 28
2025
Q3
$67.9M Sell
695,568
-19,199
-3% -$1.99M 1.3% 25
2025
Q2
$76.8M Sell
714,767
-27,889
-4% -$2.82M 1.56% 22
2025
Q1
$74.9M Buy
742,656
+1,850
+0.2% +$186K 1.79% 19
2024
Q4
$66.2M Sell
740,806
-23,038
-3% -$2.03M 1.44% 25
2024
Q3
$64M Sell
763,844
-3,476
-0.5% -$274K 1.37% 26
2024
Q2
$59.1M Buy
767,320
+11,606
+2% +$850K 1.33% 25
2024
Q1
$51.8M Buy
755,714
+24,543
+3% +$1.58M 1.2% 30
2023
Q4
$42.3M Sell
731,171
-11,434
-2% -$610K 1.09% 39
2023
Q3
$39.2M Sell
742,605
-21,108
-3% -$1.11M 1.16% 34
2023
Q2
$41.3M Sell
763,713
-324,351
-30% -$16.9M 1.12% 34
2023
Q1
$54.4M Sell
1,088,064
-10,834
-1% -$511K 1.58% 18
2022
Q4
$50.8M Sell
1,098,898
-23,678
-2% -$1.03M 1.57% 22
2022
Q3
$43.5M Sell
1,122,576
-4,337
-0.4% -$174K 1.37% 27
2022
Q2
$42M Sell
1,126,913
-27,767
-2% -$1.13M 1.27% 29
2022
Q1
$51.1M Buy
1,154,680
+38,621
+3% +$1.67M 1.2% 31
2021
Q4
$47.4M Sell
1,116,059
-298,613
-21% -$12.5M 1.02% 34
2021
Q3
$61.4M Buy
1,414,672
+868,038
+159% +$38.4M 1.44% 28
2021
Q2
$23.4M Buy
546,634
+29,479
+6% +$1.24M 0.54% 43
2021
Q1
$20M Sell
517,155
-1,705
-0.3% -$64.5K 0.49% 51
2020
Q4
$18.7M Sell
518,860
-873,677
-63% -$31.5M 0.48% 55
2020
Q3
$53.2M Sell
1,392,537
-39,683
-3% -$1.53M 1.51% 24
2020
Q2
$50.3M Sell
1,432,220
-463,369
-24% -$16.7M 1.52% 23
2020
Q1
$61.9M Buy
1,895,589
+415,093
+28% +$16.2M 2.2% 11
2019
Q4
$66.9M Sell
1,480,496
-18,725
-1% -$784K 1.99% 13
2019
Q3
$61M Buy
1,499,221
+306,933
+26% +$13M 1.98% 19
2019
Q2
$51.2M Sell
1,192,288
-32,961
-3% -$1.27M 1.61% 25
2019
Q1
$47M Buy
1,225,249
+9,319
+0.8% +$356K 1.47% 31
2018
Q4
$43M Sell
1,215,930
-9,667
-0.8% -$351K 1.56% 29
2018
Q3
$47.2M Sell
1,225,597
-21,455
-2% -$749K 1.41% 33
2018
Q2
$40.8M Buy
1,247,052
+32,009
+3% +$965K 1.34% 33
2018
Q1
$33.2M Buy
1,215,043
+22,857
+2% +$621K 1.11% 36
2017
Q4
$29.6M Sell
1,192,186
-26,292
-2% -$725K 0.96% 45
2017
Q3
$35.5M Sell
1,218,478
-21,031
-2% -$581K 1.23% 34
2017
Q2
$34.4M Sell
1,239,509
-44,172
-3% -$1.17M 1.21% 37
2017
Q1
$31.9M Sell
1,283,681
-67,344
-5% -$1.64M 1.12% 41
2016
Q4
$29.2M Sell
1,351,025
-114,851
-8% -$2.51M 1.04% 39
2016
Q3
$34.9M Sell
1,465,876
-69,773
-5% -$1.66M 1.21% 35
2016
Q2
$35.9M Sell
1,535,649
-1,738,640
-53% -$37.6M 1.2% 33
2016
Q1
$61.6M Buy
3,274,289
+271,413
+9% +$4.77M 1.94% 15
2015
Q4
$55.4M Sell
3,002,876
-78,606
-3% -$1.41M 1.65% 27
2015
Q3
$50.6M Sell
3,081,482
-436,890
-12% -$7.47M 1.61% 27
2015
Q2
$62.3M Buy
3,518,372
+698,827
+25% +$12.5M 1.71% 22
2015
Q1
$50M Buy
+2,819,545
New +$44.6M 1.33% 35

Other funds holding BSX

Atalanta Sosnoff Capital's BSX Position: Q2 2026 in Review

Atalanta Sosnoff Capital sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 402,714 shares — an estimated $25.3M sold.

Atalanta Sosnoff Capital first reported a position in BSX in Q1 2015 and held it in 45 quarters. The position peaked at $76.8M in Q2 2025. 1,465 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Atalanta Sosnoff Capital reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
  • Atalanta Sosnoff Capital sold 402,714 Boston Scientific shares in Q2 2026, an estimated $25.3M.
  • Atalanta Sosnoff Capital first reported a position in Boston Scientific in Q1 2015 and held it in 45 quarters.
  • Atalanta Sosnoff Capital's Boston Scientific position peaked at $76.8M in Q2 2025.
  • 1,465 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Atalanta Sosnoff Capital's 13F filing for Q2 2026, filed 12 Aug 2026.